Status:

TERMINATED

Early Response Evaluation in NSCLC Patients Treated With Immunotherapy

Lead Sponsor:

The Netherlands Cancer Institute

Collaborating Sponsors:

Bristol-Myers Squibb

Conditions:

NSCLC, Stage IV

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

A pilot study with biomarker exploration.50 patients with stage IV non-small cell lung cancer (NSCLC) that are eligible for treatment with nivolumab. Patients will undergo a 18F-FDG-PET/CT and EBUS-FN...

Detailed Description

Early response evaluation with 18F-FDG PET/CT and immunological profiling of circulating immune cells and tumor-draining lymph nodes in non-small cell lung cancer patients treated with immunotherapy.

Eligibility Criteria

Inclusion

  • willing and able to provide written informed consent for the study.
  • ≥ 18 years of age on day of signing informed consent.
  • confirmed diagnosis of NSCLC.
  • Histological tumor biopsy for PD-L1 IHC assessment (DAKO assay) available.
  • Ipsilateral hilar or mediastinal lymph node with a short axis diameter ≥1 cm.
  • Eligible and planned to receive nivolumab according to EMA label and national guidelines.
  • Measurable disease according to RECIST v1.1.
  • WHO performance status of 0-2.

Exclusion

  • Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to baseline PET-scan.
  • Has an active infection or had an active infection within 2 weeks prior to baseline PET-scan.
  • Has a known history of hypersensitivity to contrast material.
  • Isolated distant relapse after curative intent treatment for stage I-III NSCLC.

Key Trial Info

Start Date :

January 23 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 22 2020

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT04082988

Start Date

January 23 2018

End Date

May 22 2020

Last Update

October 10 2023

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

VU medical center

Amsterdam, Netherlands, 1007 MD

2

Leiden University Medical Center

Leiden, Netherlands, 2333 ZA